Advair Diskus Powder
Product Images NDC 50090-4502

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Advair Diskus (NDC 50090-4502). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)

Fluticasone Propionate Chemical Structure (Advair Diskus Spl Graphic 01)
FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)

Salmeterol Xinafoate Chemical Structure (Advair Diskus Spl Graphic 02)
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 03)
Not available.*
FDA Label Image

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)

S:\project Files\a\advair Diskus Nda 021077\figures\advair-diskus-spl-graphic-04.jpg (Advair Diskus Spl Graphic 04)
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Advair Diskus Spl Graphic 05)
FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 06)
FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Advair Diskus Spl Graphic 07)
FDA Label Image

Figure A (Advair Diskus Spl Graphic 08)

Figure A (Advair Diskus Spl Graphic 08)
Not available*
FDA Label Image

Figure B (Advair Diskus Spl Graphic 09)

Figure B (Advair Diskus Spl Graphic 09)
FDA Label Image

Figure C (Advair Diskus Spl Graphic 10)

Figure C (Advair Diskus Spl Graphic 10)
FDA Label Image

Figure D (Advair Diskus Spl Graphic 11)

Figure D (Advair Diskus Spl Graphic 11)
FDA Label Image

Figure E (Advair Diskus Spl Graphic 12)

Figure E (Advair Diskus Spl Graphic 12)
FDA Label Image

Figure F (Advair Diskus Spl Graphic 13)

Figure F (Advair Diskus Spl Graphic 13)
FDA Label Image

Figure G (Advair Diskus Spl Graphic 14)

Figure G (Advair Diskus Spl Graphic 14)
FDA Label Image

Figure H (Advair Diskus Spl Graphic 15)

Figure H (Advair Diskus Spl Graphic 15)
FDA Label Image

Label Image (Lbl500904502)

Label Image (Lbl500904502)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.